Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunology
Researchers from University of Freiburg, Institute of Medical Microbiology and Hygiene report on findings in immunology
December 10th, 2008
Researchers detail in 'Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy,' new data in immunology. "We determined the efficacy of in vitro expanded P14 TCR transgenic CD8 T cells to mediate tumor cell elimination and to protect against viral infection in mice. Contrary to previous studies, an adoptive transfer model without lymphodepletion, vaccination or cytokine treatment was used," scientists in Germany report. "Antigen-activated P14 T cells cultured in IL-2-containing medium for 7 days (P14IL-2) exhibited potent effector cell functions in vitro but did not confer protection against melanoma growth or viral infection. In contrast, P14 T...
Source: Vaccine Weekly (2008-12-10)
|
